Skystar Bio-Pharmaceutical to File Financial Results for Second Quarter of Fiscal 2014 on Thursday, August 14 Conference Call to Follow Friday, August 15, 2014 at 7:45 AM (ET) XI'AN, CHINA -- (Marketwired) -- 08/14/14 -- Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the second quarter of fiscal 2014 on Thursday, August 14, 2014 by close of the business day. Conference Call Information The Company will host a conference call on Friday, August 15, 2014 to discuss its financial results for the quarter ended June 30, 2014. Skystar's conference call will begin promptly at 7:45 a.m. EDT to review second quarter fiscal 2014 financial and operational performance. Mr. Weibing Lu, Skystar's Chairman and Chief Executive Officer, will host the call, which will be webcast live. Webcast will be made available on the investor relations section of the Skystar corporate website at http://www.investorcalendar.com/IC/CEPage.asp?ID=173097. Phone dial-in to the conference call will be available in North America by dialing +1 (877) 407-8031 or internationally by dialing +1 (201) 689-8031. An audio replay of the conference call will be available approximately two hours following the conclusion of the call and for the following 30 day period. To access the replay in North America, dial +1 (877) 660-6853 or, when calling internationally, dial +1 (201) 612-7415, referencing conference ID # 13589170. To be added to the Company's email distribution for future news releases, please send your request to firstname.lastname@example.org. About Skystar Bio-Pharmaceutical Company Skystar is a China-based developer, manufacturer and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics, vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities. Skystar's distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements covering 29 provinces throughout China. For additional inf ormation, please visit http://www.skystarbio-pharmaceutical.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. Contacts: Skystar Bio-Pharmaceutical Company Scott Cramer Director - Corporate Development & U.S. Representative (407) 645-4433 Grayling Investor Relations Christopher Chu (908) 251-9869 email@example.com
Press spacebar to pause and continue. Press esc to stop.